Source briefing
Human medicines European public assessment report (EPAR): Zokovea, ensitrelvir, Status: Opinion
Human medicines European public assessment report (EPAR): Zokovea, ensitrelvir, Status: Opinion
Read →
Source briefing
Human medicines European public assessment report (EPAR): KemSu, sufentanil,ketamine, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): KemSu, sufentanil,ketamine, Status: Opinion under re-examination
Read →Source briefing
Human medicines European public assessment report (EPAR): Nivestim, filgrastim, Date of authorisation: 07/06/2010, Revision: 33, Status: Authorised
Human medicines European public assessment report (EPAR): Nivestim, filgrastim, Date of authorisation: 07/06/2010, Revision: 33, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Tavneos, avacopan, Date of authorisation: 11/01/2022, Revision: 9, Status: Revoked
Human medicines European public assessment report (EPAR): Tavneos, avacopan, Date of authorisation: 11/01/2022, Revision: 9, Status: Revoked
Read →Source briefing
Human medicines European public assessment report (EPAR): Andembry, garadacimab, Date of authorisation: 10/02/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Andembry, garadacimab, Date of authorisation: 10/02/2025, Revision: 1, Status: Authorised
Read →Source briefing
Communicable disease threats report, 8 – 14 August 2026, week 33
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8 - 14 August 2026, and includes updates on Ebola, chikungunya, dengue, West Nile Virus infection, Crimean-Congo haemorrhagic fever, Vibrio, respiratory virus epidemiology in the…
Read →Source briefing
Improved Case Detection of Fleaborne Typhus by PCR Testing, Los Angeles County, California, USA, 2022–2024
A. Sanosyan et al.
Read →Source briefing
Annex 4 – Big MS Data (BMSD) feasibility study
Annex 4 - Big MS Data (BMSD) feasibility study
Read →Source briefing
Opinions and letters of support on the qualification of novel methodologies for medicine development
Opinions and letters of support on the qualification of novel methodologies for medicine development
Read →Source briefing
European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting with all eligible organisations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 October 2026, 09:00 (CEST) to 21 October 2026, 16:15 (CEST)
European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting with all eligible organisations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 October 2026, 09:00 (CEST) to 21 October 2026, 16:15 (CEST)
Read →